|
Post by seanismorris on Jul 31, 2014 18:46:34 GMT -5
The market for Afrezza is only getting larger...
DEBORAH WEINSTEIN JULY 31, 2014
HHS shows how diabetes adds up Diabetes can be a business opportunity for a pharmaceutical company—but it can also be a drag on the economy if looking at state health costs. A report released by the Department of Health and Human Services Thursday shows why. The condition, which is associated with other health risks including heart disease and eye disease, triggers around $245 billion in condition-maintenance costs a year, and diabetes patients tend to have health expenses that are 2.3% higher than patients who do not have blood-sugar issues.
A more granular look shows just how these larger numbers add up, and it's not just because diabetes medications are the most expensive non-specialty treatments. HHS reports that the number of doctor visits for diabetes patients totaled 53.7 million visits for patients 65 and older, which averages to around 1,380 visits per 1,000 patients. Younger diabetics, meaning 25 and below, averaged around 20 visits per 1,000 patients.
Diabetes patients were also plagued by multiple chronic conditions, with the number of chronic problems increasing with the patient's age. While over half of the 25-and-under diabetic patients had at least two co-morbid conditions, 35% of the 65-and-over crowd were juggling at least four.
And here's where the opportunity/money-eating divide surfaces: 85% of physician visits ended with a prescription or a patient's being directed to stick with the medications they've got.
The number of medications patients end up juggling increases with age—35% of visits by diabetics between the ages of 25 and 44 concluded with the patient being told to stick with a medication regimen that included at least five drugs, or being given additional prescriptions that brought their diabetes-related prescription load to five or more. Senior diabetics also ended up wrestling with five or more diabetes medications, but in this case that final count occurred at 60% of the visits.
|
|
|
Post by Chris-C on Jul 31, 2014 23:29:04 GMT -5
Here is yet another article by Dr. Tran. Even with distracting grammar and syntax issues set aside, I'm not sure that this guy's articles are very reassuring. For me, anyway, they don't indicate that he is attempting to provide a balanced perspective. I'm a long investor who believes in MNKD and its potential, but I don't generally call hedge funds who are attempting to manipulate the stock to better understand their POV (assuming they have a reasoned argument) nor do I call IR at MNKD and request to speak to the executives for a status report. Why bother? If they are in the midst of a negotiation, they won't be revealing that to people who call. And if they aren't, chances are they won't reveal that either. www.gurufocus.com/news/270815/amidst-whirlwind-of-opinions-from-tourbillon-mannkind-shareholders-remain-strongTo be most effective as an advocate for long investors, Dr. Tran should be modeling patience. All in my humble opinion, of course. GLTAL Chris
|
|
|
Post by seanismorris on Aug 1, 2014 11:59:47 GMT -5
Jardiance achieves regulatory clearance • 12:54 PM The FDA approves Boehringer Ingelheim and Eli Lilly's (LLY -1.3%) Jardiance (empagliflozin) as a treatment for glycemic control in addition to diet and exercise in adults with type 2 diabetes. Empagliflozin is a sodium glucose co-transporter 2 inhibitor. It blocks the reabsorption of glucose by the kidney thereby increasing glucose excretion and lowering the level of glucose in the blood. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm407637.htm---- The post marketing studies are perfectly normal.... The FDA is requiring four postmarketing studies for Jardiance: Completion of an ongoing cardiovascular outcomes trial. A pediatric pharmacokinetic/pharmacodynamic study. A pediatric safety and efficacy study. As part of the safety and efficacy study, the effect on bone health and development will be evaluated. A nonclinical (animal) juvenile toxicity study with a particular focus on renal development, bone development, and growth.
|
|
|
Post by brentie on Aug 1, 2014 19:34:40 GMT -5
|
|
|
Post by seanismorris on Aug 1, 2014 20:20:25 GMT -5
Brentie,
Nice article.
I always thought the fact Afrezza (or any other Technosphere powder) didn't need refrigeration was an important selling point (in many markets) but it's rarely brought up.
Of course, pills also don't require refrigeration but they are inferior...
|
|
|
Post by jake10977 on Aug 2, 2014 2:47:55 GMT -5
Brentie, Nice article. I always thought the fact Afrezza (or any other Technosphere powder) didn't need refrigeration was an important selling point (in many markets) but it's rarely brought up.
Of course, pills also don't require refrigeration but they are inferior... I believe it does need to be refrigerated but not between 59 - 86F degrees. See page 20 under storage. www.mannkindcorp.com/Collateral/Documents/English-US/Afrezza_PrescribingInformation.pdf
|
|
|
Post by BD on Aug 2, 2014 9:40:47 GMT -5
Thanks, Jake...just to be clear, what those specs state is that when refrigerated, it's good to the expiration date; when stored at room temp, it should be used within 10 days.
|
|
|
Post by joeypotsandpans on Aug 2, 2014 10:05:38 GMT -5
Yesterday I saw a new JDRF ad with Ray Allen, his wife and his son Walker. Since his son was diagnosed with T1 Ray has been active with the JDRF...wonder how much he is aware of Afrezza (hint of sarcasm) anyway came across the following with the visual of the tub of needles...obviously not all of them would be replaced (at least until the artificial pancreas becomes a reality) but even reducing a decent portion of them would be welcomed I'm sure. basketballbicker.com/ray-allen-shares-trials-diabetes-son-real-bucket-needles-photo/#
|
|
|
Post by mannmade on Aug 2, 2014 11:08:36 GMT -5
Joey, I have spoken to Matt a few times about a potential list of people that might work for helping to create an awareness for Afrezza when they begin the marketing and campaign effort.. (Think a PSA like campaign in the style of NBC's "The More You Know") Among others I have mentioned; Ray Allen with his son, the owner of the Utah Jazz (inherited from his father) watched his father die in his early 60's from non-compliance with T2, Halle Berry, and Bret Michels (Band Poison) the current or former King of Saudi Arabia (can't remember which) and quite a few others. I also know an 18 yr old on youtube with a few million followers who is T1 and he has offered to promote. So the possibilities will be endless...
Having said the above, I think it really comes down to the partner and what direction they think they want to take and whether Mannnkind sees it the same way. I have worked 30 years in entertainment specializing in advertising and marketing and actually have done several campaigns with pharmaceutical products some featuring public figures and celebrities. It can be a fine line and with some there is some concern about stigma although I don't think this will be the case as Mary Tyler Moore broke the ice with that... followed by Ray Allen and now Tom Hanks...
A good idea but will need to be part of an overall longterm strategy...
|
|
|
Post by joeypotsandpans on Aug 2, 2014 11:24:27 GMT -5
Joey, I have spoken to Matt a few times about a potential list of people that might work for helping to create an awareness for Afrezza when they begin the marketing and campaign effort.. (Think a PSA like campaign in the style of NBC's "The More You Know") Among others I have mentioned; Ray Allen with his son, the owner of the Utah Jazz had his father (who originally bought the Jazz) die in his earily 60's from non-compliance with T2, Halle Berry, and Bret Michels (Band Poison) the current or former King of Saudi Arabia (can't remember which) and quite a few others. I also know an 18 yr old on youtube with a few million followers who is T1 and he has offered to promote. So the possibilities will be endless... Having said the above, I think it really comes down to the partner and what direction they think they want to take and whether Mannnkind sees it the same way. I have worked 30 years in entertainment specializing in advertising and marketing and actually have done several campaigns with pharmaceutical products some featuring public figures and celebrities. It can be a fine line and with some there is some concern about stigma although I don't think this will be the case as Mary Tyler Moore broke the ice with that... followed by Ray Allen and now Tom Hanks... A good idea but will need to be part of an overall longterm strategy... And most recently the powerful inspiration brought on by Sierra Sandison www.huffingtonpost.ca/2014/07/22/diabetic-beauty-queen-sierra-sandison_n_5609888.html
|
|
|
Post by mannmade on Aug 2, 2014 14:43:45 GMT -5
Joey, I have spoken to Matt a few times about a potential list of people that might work for helping to create an awareness for Afrezza when they begin the marketing and campaign effort.. (Think a PSA like campaign in the style of NBC's "The More You Know") Among others I have mentioned; Ray Allen with his son, the owner of the Utah Jazz had his father (who originally bought the Jazz) die in his earily 60's from non-compliance with T2, Halle Berry, and Bret Michels (Band Poison) the current or former King of Saudi Arabia (can't remember which) and quite a few others. I also know an 18 yr old on youtube with a few million followers who is T1 and he has offered to promote. So the possibilities will be endless... Having said the above, I think it really comes down to the partner and what direction they think they want to take and whether Mannnkind sees it the same way. I have worked 30 years in entertainment specializing in advertising and marketing and actually have done several campaigns with pharmaceutical products some featuring public figures and celebrities. It can be a fine line and with some there is some concern about stigma although I don't think this will be the case as Mary Tyler Moore broke the ice with that... followed by Ray Allen and now Tom Hanks... A good idea but will need to be part of an overall longterm strategy... And most recently the powerful inspiration brought on by Sierra Sandison www.huffingtonpost.ca/2014/07/22/diabetic-beauty-queen-sierra-sandison_n_5609888.htmlActually sent the article to Matt when it came out...
|
|
|
Post by seanismorris on Aug 2, 2014 17:16:41 GMT -5
With regards to insulin storage, vial vs Afrezza Afrezza Additional info: insulin exposed to temperatures higher than 98.6°F (37°C) should be discarded. Store unopened product in refrigerator. If a foil packet is not refrigerated, the contents must be used within 10 days. Inhaler may be stored refrigerated, but should be at room temperature before using. Before use, cartridges should be at room temperature for 10 minutes. Source: diabetesincontrol.com Insulin Bottles of insulin, either open or unopened, generally last for one month when stored at room temperature (59 to 86°F). A bottle is considered open if its seal has been punctured. If you remove the cap but don't puncture the seal, the bottle is still considered unopened. If stored in a refrigerator, unopened bottles are good until the expiration date printed on the bottle. Opened bottles that are stored in a refrigerator should be used within one month of being opened. Many people store their unopened bottles in the refrigerator and keep open bottles at room temperature because they find it uncomfortable to inject cold insulin. Don't use bottled insulin past the expiration date printed on the label. And no matter what the expiration date is, throw away a bottle one month after you open it. To help you keep track, write the date that you opened the bottle on the bottle's label. With insulin pens and their cartridges, storage life ranges from seven days to one month. Check the chart below for shelf life details on popular brands. www.bd.com/us/diabetes/page.aspx?cat=7001&id=7247---- So, Afrezza in many cases is actually at a disadvantage with regards to storage? There is a lot of posts / Articles that say Afrezza can be stored at room temp. It seems many believe they are quoting Al on this from a few years ago. I'm wondering if Afrezza requires refrigeration because of the insulin degrading because of O2 or is this going to be standard for Technosphere formulations...
|
|
|
Post by joeypotsandpans on Aug 3, 2014 14:20:23 GMT -5
What is different about this article is it is targeted for the medical community, the comments are limited to medical professionals as well from article see: "Commenting is limited to medical professionals". The article puts forth 5 "pros" and 2 "cons", you can decide for yourself the weight of the two (almost comical IMO as the author almost seemingly struggles to post the two cons) Going back to the comments, it seems the biggest concern is cost and insurers acceptance and coverage (the other commenting concerns IMO (forgive me for saying this son) shows that physicians can be ignorant human individuals also). The officers of MNKD have stated on several occasions they expect the cost to be in line with other RAA's so obviously again IMO this is one of the biggest keys in negotiations regarding agreeable margins, etc. We know it is superior to H and N (humalog and novalog) regardless of what the FDA staffers said and the inadequate label IMO, but to me what will be key when a partnership is announced is the pricing and how the hospitals will get reimbursed from insurers as well as how they tier it which according to a good friend of mine's opinion who is a pharmacist in a hospital should be formulary (see the three tier differences here: www.regencerx.com/resources/tiered/threeTier.html). The bottom line will ultimately be how the insurers perceive the benefits versus costs, and even further the longer term savings from those benefits...so the education process will not only be to the prescribing physicians but the insurance companies as well. So to summarize, we absolutely need a strong global partner with the expertise in handling both aspects of that educating process. My pharmacist friend (who in full disclosure is a fellow longer term shareholder/investor) believes as most of us do, that with a major player announcement and it's game over for the doubters and most likely eventually the competition.
|
|
|
Post by a1nb2p on Aug 4, 2014 13:28:57 GMT -5
Central Depository registered RoClear financial instruments issued by MannKind Corporation Central Depository registered clearing-settlement and registry RoClear to conduct cross-border settlement transactions, financial instruments issued by MannKind Corporation, a release of DC, sent Monday AGERPRES. According to the document, it is about shares (symbol: MNKD) stock listed on NASDAQ, Frankfurt Stock Exchange, Berlin Stock Exchange Munich Stock Exchange Stuttgart Stock Exchange, TradeGate, BATS U.S.. Depositary is U.S. DTC. According to the Central Depository MannKind Corporation is a biopharmaceutical company focused on discovering, developing and commercializing therapeutic products for patients diagnosed with diseases such as diabetes. www.economica.net/depozitarul-central-a-inregistrat-in-sistemul-roclear-instrumentele-financiare-emise-de-mannkind-corporation_85358.htmlTranslation by Google.
|
|
|
Post by dreamboatcruise on Aug 4, 2014 13:45:14 GMT -5
Translation by Google. Can someone translate the translation? Is this basically MNKD getting listed on EU exchanges like ADR are here for foreign stocks?
|
|